Avalyn Pharma Is A Clinical Stage Biopharmaceutical Company Dedicated To Developing Innovative Inhaled Therapies For Rare Respiratory Diseasesparticularly Pulmonary Fibrosis And Other Interstitial Lung Diseasesthe Company Aims To Improve Patient Outcomes By Delivering Effective Medications Directly To Lung Tissuewhich Helps Reduce Systemic Exposure And Side Effects Associated With Traditional Oral Drug Delivery Led By Ceo Lyn Baranowski And Cso Mark Surberphdavalyn Pharma Is Advancing A Pipeline That Includes Inhaled Formulations Of Existing Oral Anti Fibrotic Drugs Like Pirfenidone And Nintedanibtheir Productssuch As Ap01 And Ap02Focus On Maximizing The Therapeutic Effects Of These Drugs While Minimizing Side Effectsadditionallyap03 Is A Fixed Dose Combination Of Pirfenidone And Nintedanib Designed For Inhaled Deliveryaiming To Enhance Efficacy Without The Additive Side Effects Of Oral Formulationsavalyn Pharma Is Headquartered In Cambridgemaand Is Supported By Investors Like Catalio Capital Management
